Uterine Artery Color Doppler Parameters After Bilateral Uterine Artery Ligation

Sponsor
Tanta University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05584995
Collaborator
(none)
70
2
12

Study Details

Study Description

Brief Summary

The aim of this study is to assess Uterine artery color doppler parameters after bilateral uterine artery ligation (BUAL) for Postpartum Hemorrhage.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Control group
  • Procedure: BUAL group
N/A

Detailed Description

Obstetric haemorrhage is the main reason of maternal death in both countries with high and poor incomes. Most of these deaths occurred within the first 24 hours following birth. Placenta accrete, retained placenta, genital tract lacerations, uterine rupture, and coagulation abnormalities are established risk factors for postpartum hemorrhage. The management of Idiopathic pulmonary hemosiderosis (IPH) and postpartum hemorrhage relies on numerous considerations: type of delivery (vaginal or caesarean delivery), bleeding etiology (uterine atony, trauma, retained placenta) and hemodynamic stability.

In the first stage, early identification, and treatment with uterotonics, suturing the lacerations, and fundal massage are crucial. When bleeding persist, even in the aggressive medical treatment, suitable surgical intervention should be performed.

Surgical therapy relies on the patient's desire to maintain fertility, the severity of the bleeding, and the surgeon's experience.

Historically, peripartum hysterectomy was the only available management to prevent postpartum hemorrhage but, in some instances, hysterectomy alone is insufficient to control the bleeding.

Also, the desire to preserve fertility have resulted in the development of other techniques, such as pelvic embolization and internal iliac artery ligation (IIAL)and bilateral uterine artery ligation (BUAL).

Bilateral uterine artery ligation (BUAL) is the most popular surgical procedure for quick management of postpartum hemorrhage. It may be performed alone or with conjugation with other postpartum hemorrhage methods in with success rate exceeds 90 %. Recanalization is a natural process that may occur following vascular structure closure with a suture or radiological embolization.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Uterine Artery Color Doppler Parameters After Bilateral Uterine Artery Ligation for Postpartum Hemorrhage
Anticipated Study Start Date :
Oct 20, 2022
Anticipated Primary Completion Date :
Oct 20, 2023
Anticipated Study Completion Date :
Oct 20, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Control group

Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)

Procedure: Control group
Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)

Experimental: BUAL group

Cases will undergo Bilateral Uterine Artery Ligationafter Postpartum Hemorrhage after cesarean section resistant to medical treatment and did not need a hysterectomy.

Procedure: BUAL group
Bilateral Uterine Artery Ligation Technique: All uterine surgeries will be conducted by externalizing the uterus as much as possible and holding it by the fundus. The BUAL will be done using absorbable suture no. 1 Vicryl (Vicryl 1, Ethicon, France, Neuvilly-sur-Seine, France) will be placed through an avascular space in the broad ligament and tied from the anterior to posterior aspects of the myometrium 2-3 cm medial to the descending portion of the uterine vessels. In all patients, the suture will be carried from the anterior to the posterior at 1 cm to the myometrium medial to the Uterine artery and will be knotted after passing it through the avascular region at 1 cm to the wide ligament section adjacent to the uterus in both sides. All patients will be examined for uterotonics during and after the surgery. The ovarian arteries will be assessed at the level of the ovarian hilum.

Outcome Measures

Primary Outcome Measures

  1. Color Doppler parameters [After Bilateral Uterine Artery Ligation]

    Color Doppler parameters for measuring the UtA diameters as UtA pulsatility Index will be recorded

Secondary Outcome Measures

  1. The uterine artery's descending branches [After Bilateral Uterine Artery Ligation]

    The uterine artery's descending branches will be measured at the level of the internal os of the uterine cervix.

  2. The uterine artery's ascending branch [After Bilateral Uterine Artery Ligation]

    The uterine artery's ascending branch on the left and right sides of the uterine isthmus will be identified by means of color flow imaging to obtain uterine arterial blood flow velocity waveforms.

  3. Color Doppler parameters [After Bilateral Uterine Artery Ligation]

    resistance Index (RI) will be recorded

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 35 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 70 women aged between 20 and 35 years old.

  • Undergoing Bilateral Uterine Artery Ligation after Postpartum Hemorrhageafter cesarean section

  • resistant to medical treatment, and did not need to hysterectomy.

Exclusion Criteria:
  • Patients with male factor, tubal factor, and absence of lactation.

  • Diabetes mellitus, hypertension, morbid obesity, autoimmune disease, or vascular disease in the history, smoking.

  • Intrauterine growth restriction in previous pregnancies history, detection of a uterine anomaly or a medical condition, as well as administration of a hormonal treatment during the study.

  • Uncontrolled bleeding is needed for a hysterectomy.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Tanta University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ahmed Ossman, Assistant professor, Tanta University
ClinicalTrials.gov Identifier:
NCT05584995
Other Study ID Numbers:
  • 35873/9/22
First Posted:
Oct 18, 2022
Last Update Posted:
Oct 20, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 20, 2022